Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

"While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer's disease, the extensive body of ...

Chris Hemsworth shares his family's experience with reminiscence therapy — unlocking old memories to help slow the ...

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

Pharmaceutical giant Novo Nordisk says an oral version of semaglutide — the active ingredient in blockbuster drugs Ozempic ...